|Articles|May 26, 2023
Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart
Author(s)Chris Spivey
Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.
Advertisement
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
3
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
4
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
5
